Stay updated on Pegilodecakin Combo vs Pembrolizumab Alone in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pegilodecakin Combo vs Pembrolizumab Alone in NSCLC Clinical Trial page.

Latest updates to the Pegilodecakin Combo vs Pembrolizumab Alone in NSCLC Clinical Trial page
- Check3 days agoChange DetectedA site-wide notice about government funding status and NIH Clinical Center operations was added, and the page now shows a revision update from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check10 days agoChange DetectedThe updates are minor editorial changes to UI text and versioning, including adding a 'Show glossary' option, correcting capitalization in labels such as 'Last Update Submitted that met QC Criteria' and 'No FEAR Act Data', and updating the revision from v3.3.4 to v3.4.0.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedRevision: v3.3.4 was added and v3.3.3 was removed. No changes to study content or page functionality.SummaryDifference0.0%

- Check45 days agoChange DetectedAdded a comprehensive Locations section listing participating states for the Cypress-1 trial (rev. v3.3.3).SummaryDifference2%

- Check74 days agoChange DetectedThese changes are minor editorial updates to the Publications section, noting that PubMed publications are automatically populated, and the page revision has moved from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check81 days agoChange DetectedThe government funding status notice was removed from the page. This change does not modify the study details, eligibility criteria, outcomes, or other substantive content.SummaryDifference0.2%

Stay in the know with updates to Pegilodecakin Combo vs Pembrolizumab Alone in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pegilodecakin Combo vs Pembrolizumab Alone in NSCLC Clinical Trial page.